The Vaccine Contract Manufacturing Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Vaccine Contract Manufacturing Market:
https://www.thebusinessresearchcompany.com/report/vaccine-contract-manufacturing-global-market-report
According to The Business Research Company’s Vaccine Contract Manufacturing Global Market Report 2024, The vaccine contract manufacturing market size has grown strongly in recent years. It will grow from $3.3 billion in 2023 to $3.62 billion in 2024 at a compound annual growth rate (CAGR) of 9.9%. The growth in the historic period can be attributed to traditional vaccine manufacturing limitations, global disease outbreaks driving vaccine demand, regulatory support for contract manufacturing, increasing complexity of vaccine production, surge in vaccine research and development..
The vaccine contract manufacturing market size is expected to see rapid growth in the next few years. It will grow to $5.32 billion in 2028 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to growing emphasis on pandemic preparedness, increased outsourcing in pharmaceutical manufacturing, expansion of biopharmaceutical companies, accelerated vaccine development timelines, global initiatives for vaccine accessibility. Major trends in the forecast period include integration of single-use technologies in manufacturing, rise in personalized medicine approaches to vaccine development, development of mrna and viral vector vaccines, adoption of continuous manufacturing processes, expansion of fill-finish services.
An increase in initiatives favoring vaccinations is expected to propel the growth of the vaccine contract manufacturing market going forward. Vaccination refers to an easy, safe, and efficient method of defending against contagious diseases before they occur. It boosts the immune system and builds up the body’s defenses against infections. Increasing initiatives favoring vaccinations would help advance and develop various vaccine manufacturing processes to support vaccine contract manufacturing. For instance, in November 2022, the U.S. Department of Health and Human Services, a US-based cabinet-level executive branch department of the federal government, announced a new $350 million initiative for HRSA (Health Resources and Services Administration)-supported health facilities to boost the number of COVID-19 vaccines in their communities, with an emphasis on marginalized people. Therefore, the increase in initiatives favoring vaccinations is driving the growth of the vaccine contract manufacturing market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=12216&type=smp
The vaccine contract manufacturing market covered in this report is segmented –
1) By Service Type: Fill-Finish, Bulk Product
2) By Vaccine Type: Inactivated Vaccines, Live-Attenuated Vaccines, RNA (Ribonucleic Acid) Vaccines, Subunit Vaccines, Toxoid-Based Vaccines
3) By Process: Downstream, Upstream
4) By Scale Of Operation: Preclinical, Clinical, Commercial
5) By End-Use: Human Use, Veterinary
Top Major Players
Pfizer Inc.
Johnson & Johnson
AbbVie Inc.
Sanofi
GlaxoSmithKline
Strategic partnerships are a key trend gaining popularity in the vaccine contract manufacturing market. Significant companies are partnering with the companies operating in the vaccine contract manufacturing market to sustain their position in the market. For instance, in January 2023, Vaxxas, an Australia-based biotechnology company that develops a novel needle-free vaccination technology, partnered with the Coalition for Epidemic Preparedness Innovations, a Norway-based foundation, to finance and coordinate the development of new vaccines and promote the development of Vaxxas’ needle-free vaccine patch delivery technology in a project that may eliminate the frozen storage requirement for mRNA vaccines. Furthermore, in January 2021, Novartis AG, a Switzerland-based pharmaceutical company operating in the vaccine contract manufacturing market, partnered with Pfizer Inc., a US-based pharmaceutical company, and BioNTech SE, a Germany-based biotechnology company, to provide manufacturing capacity for the Pfizer-BioNTech COVID-19 vaccine. This partnership helps Novartis take bulk mRNA active ingredients from BioNTech and fill them into vials under aseptic conditions for shipment back to BioNTech for distribution to the healthcare system.
The vaccine contract manufacturing market report table of contents includes:
1. Executive Summary
2. Vaccine Contract Manufacturing Market Characteristics
3. Vaccine Contract Manufacturing Market Trends And Strategies
4. Vaccine Contract Manufacturing Market – Macro Economic Scenario
5. Global Vaccine Contract Manufacturing Market Size and Growth
………………………..
32. Global Vaccine Contract Manufacturing Market Competitive Benchmarking
33. Global Vaccine Contract Manufacturing Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Vaccine Contract Manufacturing Market
35. Vaccine Contract Manufacturing Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
